Related Experiment Video
Updated: Sep 20, 2026
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
Stem cell therapy for the infarcted heart ("cellular cardiomyoplasty")
Thomas J Dengler1, Hugo A Katus
1Department of Cardiology, Internal Medical Clinic III, University of Heidelberg, Germany. thomas.dengler@urz.uni-heidelberg.de
Insights
Stem cell therapy offers new hope for heart attack patients by regenerating damaged heart muscle. This approach, known as cellular cardiomyoplasty, aims to replace cardiac myocytes lost after myocardial infarction.
Area of Science:
- Regenerative Medicine
- Cardiology
- Stem Cell Biology
Background:
- Myocardial infarction (MI) is a primary cause of heart failure, with current treatments often failing to prevent adverse left ventricular remodeling.
- Necrotic cardiac myocytes are not effectively replaced by existing therapies, highlighting a critical unmet need in cardiovascular medicine.
Purpose of the Study:
- To review current understanding of stem cell mobilization to the infarcted heart.
- To discuss cell-based therapeutic concepts for myocardial infarction regeneration.
- To provide an overview of ongoing clinical trials and future research directions.
Main Methods:
- Literature review of stem cell biology and regenerative medicine in the context of myocardial infarction.
- Analysis of various cell types investigated for cardiac repair (e.g., stem cells, skeletal myoblasts, endothelial precursors).
- Summary of clinical trial progress and identification of key research goals.
Main Results:
- Physiological stem cell mobilization occurs in response to myocardial infarction.
- Multiple cell types show potential for cardiac regeneration, including adult/embryonic stem cells, skeletal myoblasts, and endothelial precursors.
- Ongoing clinical trials are evaluating the efficacy of these cell-based therapies.
Conclusions:
- Cell-based therapies, or cellular cardiomyoplasty, hold significant promise for treating myocardial infarction and preventing heart failure.
- Further rigorously designed patient trials are essential to define optimal strategies and clinical outcomes.
- Advancements in stem cell biology are paving the way for novel regenerative approaches in cardiology.
Background:
Myocardial infarction is the leading cause of heart failure in developed countries, because even the advanced therapeutic measures of today are usually not sufficient to prevent left ventricular remodeling as they fall short of actual replacement of necrotic cardiac myocytes. Recent new insights into stem cell biology have changed our understanding of regenerative activities in the infarcted heart and have raised considerable hopes for novel therapeutic approaches aimed at cardiac myocyte replacement/regeneration through cell transplantation ("cellular cardiomyoplasty"). CELL-BASED THERAPEUTIC CONCEPTS: This review summarizes our present understanding of physiological stem cell/precursor cell mobilization to the infarcted heart and discusses the main therapeutic concepts for cell-based regeneration of myocardial infarction (adult/embryonic stem cells, skeletal myoblasts, endothelial precursors and others), including a brief overview of ongoing clinical trials. Finally, a shortlist of central clinical and research goals is provided, which should be addressed by stringently designed patient trials.
